A Memorandum of Understanding (MoU) has been signed between Hoa Lam Shangri-La Healthcare, part of Hoa Lam Group, and Cyto-Facto Inc., a company based in Japan. The agreement outlines plans to establish a quality control center for cells and stem cells in Vietnam. The center is expected to adhere to international standards for stem cell production and therapies.
According to the MoU, the two organizations will collaborate on advancing cell therapy, stem cell treatments, and gene therapy. Cyto-Facto Inc. said that they will provide training, consultation, and technology transfer, with a focus on mesenchymal stem-cell production from knee synovial membrane, following Japanese quality control standards. Additionally, automated cell processing systems will be introduced at Hoa Lam Shangri-La Healthcare’s facilities.
The collaboration is expected to contribute to the development of the Hoa Lam Shangri-La High-Tech Medical Zone in Bình Tân district, which aims to offer medical services at international standards. The zone will place a particular emphasis on regenerative medicine.
This partnership is seen as a step toward introducing these technologies to Vietnam, with a focus on addressing chronic and severe health conditions.
